alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

30,580 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 551–575 of 639 studies in Prevention and risk · free to read (page 23 of 26) · 30,580 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 16,054 studies have no institution on record and are not counted here.

What “Prevention and risk” covers

Prevention and risk — What might lower the risk of dementia — and what happened when those things were properly tested.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Therapies for Prevention and Treatment of Alzheimer's Disease

✓ Peer-reviewed alzhub usefulness score 43 out of 100. BioMed research international 2016-07-28

Alzheimer's disease (AD) is the most common cause of dementia associated with a progressive neurodegenerative disorder, with a prevalence of 44 million people throughout the world in 2015, and this figure is estimated to double by 2050. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Diet, nutrition and the ageing brain: current evidence and new directions

✓ Peer-reviewed alzhub usefulness score 43 out of 100. The Proceedings of the Nutrition Society 2018-01-10

Globally populations are ageing. By 2050, it is estimated that there will be two billion people aged 60 years or over, of which 131 million are projected to be affected by dementia, while depression is predicted to be the second leading cause of disability worldwide by 2020. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Associations Between Self-Reported Sensory Impairment and Risk of Cognitive Decline and Impairment in the Health and Retirement Study Cohort

✓ Peer-reviewed alzhub usefulness score 43 out of 100. The journals of gerontology. Series B, Psychological sciences and social sciences 2020-06-01

Self-assessed sensory impairment is independently associated with cognitive decline and incident possible CIND and probable dementia. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Precision to plate: AI-driven innovations in fermentation and hyper-personalized diets

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Frontiers in Nutrition 2025-09-04

The global food system faces unprecedented challenges, including climate-driven agricultural instability, rising malnutrition, and consumer demand for sustainable yet appealing products. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The Role of Oxidative Damage in the Pathogenesis and Progression of Alzheimer's Disease and Vascular Dementia

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Oxidative medicine and cellular longevity 2015-08-02

Oxidative stress (OS) has been demonstrated to be involved in the pathogenesis of the two major types of dementia: Alzheimer's disease (AD) and vascular dementia (VaD). 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Prophylactic effects of nutrition, dietary strategies, exercise, lifestyle and environment on nonalcoholic fatty liver disease

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Annals of Medicine 2025-02-12

Reasonable nutrient intake encompassing macronutrients and micronutrients have an independent protective relationship with NAFLD. 5 key findings →

Design: narrative review Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

From Mandates to Mechanisms: Institutional Vulnerability, Decentralized Governance, and the Challenges of Local Disaster Risk Reduction Implementation

✓ Peer-reviewed alzhub usefulness score 42 out of 100. International Journal of Disaster Risk Science 2025-10-01

The findings indicate that the deficiencies within these institutions are not merely technical but are significantly influenced by systemic disparities in power, resource allocation, and political stability. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The Role of Lifestyle and Diet in the Treatment of Endometriosis: A Review

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Nutrients 2026-01-01

Endometriosis is a chronic, oestrogen-dependent inflammatory condition affecting approximately 10% of women of reproductive age, frequently associated with chronic pelvic pain, dysmenorrhoea and infertility, substantially impairing quality of life. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 30,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,580 records, built mostly from automated pulls of Europe PMC (64.7% of the library) and OpenAlex (16.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,037 records (3.4% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events